When is MindMaze Therapeutics expected to launch MindMotion Lite?

MindMaze Therapeutics expects to launch MindMotion Lite by the end of 2026. The company said further details on commercial availability and launch markets will be shared closer to launch.

What is MindMotion Lite designed to do?

MindMotion Lite is designed to support intensive neurorehabilitation in the home. It retains full-body rehabilitation capabilities and is intended to support therapy beyond the clinic through teleconsultation and remote management.

How does MindMotion Lite differ from MindMotion GO?

MindMotion Lite delivers all neurotherapeutic activities available on MindMotion GO through a tablet, significantly reducing the hardware requirements for home deployment. MindMaze Therapeutics also said its format is designed to reduce home deployment costs compared with MindMotion GO.

How will healthcare professionals use MindMotion Lite?

Healthcare professionals will be able to use the tablet’s teleconsultation and remote-management capabilities to support patients as they continue therapy beyond the clinic. The source does not provide further operational details about this support.

Why is MindMaze Therapeutics developing a home-based neurorehabilitation solution?

MindMaze Therapeutics said continued access to neurotherapy after patients return home remains a critical gap in current care. CEO Zach Henderson said MindMotion Lite is designed to help address that gap and make intensive neurorehabilitation part of patients’ lives beyond the clinic.

What does MindMaze Therapeutics say about the commercial benefits of MindMotion Lite?

MindMaze Therapeutics said the tablet-based format is designed to enhance patient experience, streamline distribution and reduce home deployment costs compared with MindMotion GO. The company described the product as supporting a more scalable and capital-efficient expansion of its home-based offering.

How does MindMotion Lite fit into MindMaze Therapeutics’ existing business?

MindMotion Lite complements MindMaze Therapeutics’ existing platform, which combines therapeutic software, sensors and specialised hardware for neurorehabilitation across the continuum of care. The company said the new solution integrates with its suite of solutions and is eligible under its existing reimbursement codes.

What does MindMaze Therapeutics do?

MindMaze Therapeutics provides software, proprietary sensors and AI-driven data analytics for neurorehabilitation from the acute hospital phase through outpatient treatment and home-based therapy. Its FDA-listed and CE-marked products are designed for stroke, Parkinson’s disease and other neurological disorders, according to the company.

Where are MindMaze Therapeutics’ shares listed and what is the ticker symbol?

MindMaze Therapeutics’ shares are listed on SIX under the ticker symbol MMTX.

What did MindMaze Therapeutics’ CEO say about MindMotion Lite?

Zach Henderson, CEO of MindMaze Therapeutics, said the company aims to make intensive neurorehabilitation more accessible and a routine part of patients’ lives beyond the clinic. He also referred to AHA/ASA guidelines updated in August 2026 that emphasise rehabilitation intensity and continuity of care after stroke.

What will happen next with MindMotion Lite?

Ahead of the launch, MindMaze Therapeutics will preview MindMotion Lite at upcoming clinical, healthcare and investor conferences. The company said further details on commercial availability and launch markets will be shared closer to launch.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics announces planned MindMotion Lite launch by end of 2026

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics announces planned MindMotion Lite launch by end of 2026

Published Thursday, 17 September 2026, 05:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Product launch
Published: Thursday, 17 September 2026, 05:00 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics (SIX: MMTX) announced MindMotion Lite, a tablet-based version of its MindMotion neurorehabilitation activities designed for home use. The company plans to launch it by the end of 2026.

MindMotion Lite is designed to provide full-body rehabilitation activities, teleconsultation and remote management by healthcare professionals. It is intended to require less hardware than MindMotion GO and support home therapy after patients leave the clinic. The company said the product is eligible under its existing reimbursement codes.

Before launch, the company will preview MindMotion Lite at upcoming clinical, healthcare and investor conferences. It said further details about commercial availability and launch markets will be shared closer to launch.

Investor FAQs

MindMaze Therapeutics announced the launch of MindMotion Lite by the end of 2026. The tablet-based solution is designed for home use and will bring the full range of MindMotion neurotherapeutic activities to a format requiring less hardware than MindMotion GO.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Announces MindMotion Lite to Expand Home-Based Neurorehabilitation
Published: Thursday, 17 September 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…